Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Still a Buy?

Key Points

• Telix Pharmaceuticals shares fell 10.2% to $11.49, while trading volume reached approximately 190,046 shares.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $20.40, despite recent downgrades to “Hold” and “Sector Perform.”
• Institutional ownership has increased, including significant position expansions by Bank of America, Lazard Asset Management, and Private Advisor Group.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw strong trading volume on Monday . Approximately 190,046 shares were traded during trading, a decline of 9% from the previous session's volume of 209,682 shares.The stock last traded at $11.49 and had previously closed at $12.59.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Weiss Ratings raised shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research report on Friday, August 21st. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday, September 15th. Wedbush reiterated an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday, September 14th. Citigroup reiterated a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Finally, Royal Bank Of Canada cut Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.40.

Telix Pharmaceuticals Stock Down 10.2%

The firm's fifty day simple moving average is $11.30 and its 200 day simple moving average is $10.35. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16.

Institutional Trading of Telix Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its position in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock worth $96,000 after acquiring an additional 8,423 shares in the last quarter. XY Capital Ltd purchased a new position in Telix Pharmaceuticals in the first quarter valued at approximately $120,000. Lazard Asset Management LLC raised its holdings in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock worth $2,775,000 after purchasing an additional 39,400 shares in the last quarter. Private Advisor Group LLC lifted its position in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock worth $1,669,000 after buying an additional 128,070 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $1,731,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.